Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

"Declarations Ethics approval and consent to participateNot applicable. Competing interestsThe authors declare no conflict of interest. Competing interests The authors declare no conflict of interest."

"Funding This study was funded by grants from Carlos III Health Institute (PI19/00132, PI22/00085), partially supported by the European Regional Development Fund (ERDF), to L.S., and by grants from the Spanish Ministry of Science and Innovation (PID2020-117323RB-100 and PDC2021-121711-100), the Carlos III Health Institute (DTS20/00089), the CRIS Cancer Foundation (FCRIS-2021-0090), Spanish Association Against Cancer (PROYE19084ALVA), the Fundación ‘‘La Caixa’’ (HR21-00761 project IL7R_LungCan) and the Fundación de Investigación Biomédica 12 de Octubre Programa Investiga (2022-0082) to L.A-V. A.T-G. was supported by a predoctoral fellowship from Comunidad Autónoma de Madrid (PEJD-2018-PRE/BMD-8314)."